Detecting circulating tumor cells in patients with advanced non-small cell lung cancer

Xu, Yan; Zhou, Juan; Pan, X F

doi:10.4238/2015.september.1.1

Cited by 15 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correlation with survival of CTC counts was not reported by Xu and collaborators, who identified peripheral blood CTCs in 47/66 (71.2%) chemo-naïve stage IV NSCLC patients by using the CellSearch (35). However, they found that the number of patients with ≥3 CTCs decreased significantly after two cycles of chemotherapy.…”

Section: Prognostic and Predictive Value Of Ctc In Advanced Nsclcmentioning

confidence: 62%

See 1 more Smart Citation

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Gallo

Luca

Maiello

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Several different studies have addressed the role of the circulating tumor cells (CTC) in nonsmall-cell lung cancer (NSCLC). In particular, the potential of CTC analysis in the early diagnosis of NSCLC and in the prediction of the outcome of patients with early and advanced NSCLC have been explored. A major limit of these studies is that they used different techniques for CTC isolation and enumeration, they employed different thresholds to discriminate between high-and low-risk patients, and they enrolled heterogeneous and often small cohort of patients. Nevertheless, the results of many studies are concordant in indicating a correlation between high CTC count and poor prognosis in both early and advanced NSCLC. The reduction of CTC number following treatment might also represent an important indicator of sensitivity to therapy in patients with metastatic disease. Preliminary data also suggest the potential for CTC analysis in the early diagnosis of NSCLC in high-risk individuals. However, these findings need to be confirmed in large prospective trials in order to be transferred to the clinical practice.The molecular profiling of single CTC in NSCLC might provide important information on tumor biology and on the mechanisms involved in tumor dissemination and in acquired resistance to targeted therapies. In this respect, xenografts derived from CTC might represent a valuable tool to investigate these phenomena and to develop novel therapeutic strategies.

show abstract

Section: Prognostic and Predictive Value Of Ctc In Advanced Nsclcmentioning

confidence: 62%

“…However, they found that the number of patients with ≥3 CTCs decreased significantly after two cycles of chemotherapy. In this respect, a count ≥3 CTCs after two cycles was associated with an higher rate of progressive disease (P<0.05) (35).…”

Section: Prognostic and Predictive Value Of Ctc In Advanced Nsclcmentioning

confidence: 99%

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Gallo

Luca

Maiello

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…To date, "CellSearch System" is the only Food and Drug Administration (FDA)-approved technique used to detect CTCs, which uses epithelial markers like EpCAM and CKs. 3,[10][11][12][13][14]23 Epithelial cells undergo EMT to increase the capacity of invasiveness and metastasis, resulting in loss of expression of epithelial cell markers such as EpCAM and/or CKs, and thus, EpCAM-based techniques may not efficiently capture CTCs with mesenchymal characteristic following EMT. Mani et al 26 revealed that cells acquire stem-cell-like properties during EMT by up-regulation of CD44 and down-regulation of CD24 as well as increased expression of other stem cell phenotypic markers.…”

Section: Discussionmentioning

confidence: 99%

“…[7][8][9] Till date, epithelial cell surface markers are being used as a sole modality for isolation of rare population of CTCs by various systems. [10][11][12][13][14] Utilizing these markers for the effective isolation of CTCs may provide erroneous results as they result in the down-regulation of epithelial cell markers during the epithelial-mesenchymal transition (EMT). Increasing evidences suggest that an apparently small subset of CTCs also bears CSC characteristics based on their ability to give rise to tumors and thus could be considered circulating tumor stem cells (CTSCs).…”

Section: Introductionmentioning

confidence: 99%

Evidence for circulating cancer stem-like cells and epithelial–mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy

2017

View full text Add to dashboard Cite

Lung cancer stem cells are supposed to be the main drivers of tumor initiation, maintenance, drug resistance, and relapse of the disease. Hence, identification of the cellular and molecular aspects of these cells is a prerequisite for targeted therapy of lung cancer. Currently, analysis of circulating tumor cells has the potential to become the main diagnostic technique to monitor disease progression or therapeutic response as it is non-invasive. However, accurate detection of circulating tumor cells has remained a challenge, as epithelial cell markers used so far are not always trustworthy for detecting circulating tumor cells, especially during epithelial-mesenchymal transition. As cancer stem cells are the only culprit to initiate metastatic tumors, our aim was to isolate and characterize circulating tumor stem cells rather than circulating tumor cells from the peripheral blood of NSCLC adenocarcinoma as limited data are available addressing the gene expression profiling of lung cancer stem cells. Here, we reveal that CD44(+)/CD24(−) population in circulation not only exhibit stem cell-related genes but also possess epithelial-mesenchymal transition characteristics. In conclusion, the use of one or more cancer stem cell markers along with epithelial, mesenchymal and epithelial mesenchymal transition markers will prospectively provide the most precise assessment of the threat for recurrence and metastatic disease and has a great potential for forthcoming applications in harvesting circulating tumor stem cells and their downstream applications. Our results will aid in developing diagnostic and prognostic modalities and personalized treatment regimens like dendritic cell-based immunotherapy that can be utilized for targeting and eliminating circulating tumor stem cells, to significantly reduce the possibility of relapse and improve clinical outcomes.

show abstract

“…Six studies assessed the role of CTCs in chemo-naïve NSCLC patients that received standard treatment with chemotherapy [48][49][50][51][52][53] (Table 3). Krebs stage III.…”

Section: Prognostic Value Of Ctcs In Advanced/metastatic Nsclcmentioning

confidence: 99%

The prognostic role of circulating tumor cells in lung cancer

Normanno

Luca

Gallo

et al. 2016

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

The state-of-the-art of the role of CTCs in lung cancer patients is reviewed and discussed. A structured search of bibliographic databases for peer-reviewed research literature and of main meetings using a focused review question was undertaken. Expert commentary: Although in the revised studies different technologies, cutoffs, patients' populations and statistical approaches have been used, a high CTCs count as prognostic role in small-cell lung cancer is suggested, whereas additional studies are required to confirm this correlation in non-small-cell lung cancer. A reduction in CTCs count is also likely to be correlated with the lung cancer patients' outcome. Large prospective trials need to confirm the prognostic and/or predictive role of CTCs in lung cancer.

show abstract

Detecting circulating tumor cells in patients with advanced non-small cell lung cancer

Cited by 15 publications

References 9 publications

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Evidence for circulating cancer stem-like cells and epithelial–mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy

The prognostic role of circulating tumor cells in lung cancer

Contact Info

Product

Resources

About